Presenting at eCOA Forum Scientific Sessions at the University of Oxford
We are delighted to be speaking at the upcoming eCOA Forum Scientific Sessions on June 24-25 in Oxford, United Kingdom.
Hosted by CRF Health, the meeting brings together world leaders in PRO development and Health Outcomes and focuses on current approaches to questionnaire development, design, validation and migration from paper to electronic platforms as well as regulatory considerations.
Rob Arbuckle and Adam Gater, Directors within our Endpoint Development and Outcomes Assessment practice will be leading 2 of the sessions:
- Development and validation of COA instruments as eCOA from the beginning: advantages, opportunities, and challenges | June 24 11.00-11.30
- Developing pediatric COA instruments as eCOA: A case study highlighting the advantages of developing endpoints electronically | June 25 13.00-14.00
Adam Gater is also facilitating the following eCOA Best Practices and Insight Workshop:
- Developing custom questionnaires | June 24 13.30-15.4
According to a recent news release, Rachael Wyllie, CEO, CRF Health said, “The goal of the eCOA Forum Scientific Sessions is to create a forum where thought leaders can debate, exchange perspectives, and advance the acceptance of eCOA as the gold standard of patient data collection in clinical trials” Rachel goes on to say “We look forward to raising awareness and sharing the values of eCOA throughout the industry,”
If you are interested in attending the eCOA Forum, please visit the following registration page. Please note this is a limited seating program, so please register early to reserve your seat at the meeting. Please feel free to share this meeting with a colleague whom you think may benefit from attending.
Established in 1993, Adelphi Values has been a global leader in patient-centred and healthcare value research for over 20 years. Our in-depth understanding of approaches for the selection, development, validation and implementation of PRO instruments is grounded in a solid understanding of regulatory expectations and standards as well as experience in commercialisation and market access.